Vericiguat in patients with acute coronary syndrome and reduced ejection fraction: the EVE-ACSrEF study

作者：Xinying Shi, Anran Zhao, Yi Ding, Lingfeng Gu, Taoyue Yang, Hao Wang, Qiming Wang, Sibo Wang, Liansheng Wang · 发表于：BMC Cardiovascular Disorders · 年份：2026 · DOI：10.1186/s12872-026-05622-1 · 被引用次数：1 · 研究领域：Cardiac pacing and defibrillation studies、Heart Failure Treatment and Management、Cardiovascular Function and Risk Factors

BACKGROUND: Preclinical research has demonstrated that vericiguat can improve myocardial microcirculation. However, real-world evidence of using vericiguat alongside guideline-directed medical therapy (GDMT) in patients with acute coronary syndrome (ACS) complicated by heart failure with reduced ejection fraction (HFrEF) remains limited. METHODS: In this prospective cohort study, 149 ACS patients with left ventricular ejection fraction (LVEF) below 45% were grouped by their treatment preference. Multivariable analyses were used to evaluate the effect of vericiguat on the composite endpoint of hospitalization for heart failure (HHF) or cardiovascular death (CVD). A linear mixed-effects model was used to analyze changes in LVEF and N-terminal pro-brain natriuretic peptide (NT-proBNP) from baseline to 12 months. Differences in the absolute values of Kansas City Cardiomyopathy Questionnaire quality of life (KCCQ-QoL) scores during the follow-up were also evaluated. RESULTS: In this study, 75 patients (50.3%) received vericiguat plus GDMT treatment, while 74 patients (49.7%) received GDMT treatment alone. The average age of enrolled patients was 65 years, with approximately 17.4% being female. 33.6% were classified as NYHA class III heart failure, and the average LVEF was 38.11%. Over the 12-month follow-up, the composite endpoint event occurred in 5 (6.67%) of 75 patients in the vericiguat group and 13 (17.57%) of 74 patients in the GDMT group (hazard ratio [HR] 0.31 [95% confide...